Thermo Fisher Strengthens PCR Portfolio with $260M Fermentas Acquisition

Thomas Weisel Partners called Thermo Fisher's planned $260 million acquisition of Fermentas a "synergistic tuck-in deal" that "bolsters Thermo's capabilities in the high-growth PCR market."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.